Testing four breast cancer medicines for stage II–III ER+/PR+/HER2+ cancer
Part of Cancer, Skin clinical trials.
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 75
- Your breast cancer is confirmed ER-positive (>10%), PR-positive (>1%), and HER2-positive (IHC 3+ or IHC 2+ with ISH amplification)
- You have stage II or III breast cancer (not stage IV) and it’s your first time being treated for this breast cancer
- You have enough general health: good heart strength on ultrasound, acceptable EKG timing (QTc), and blood/liver/kidney tests within limits
- You can have a biopsy and agree to follow study visits and treatment plan
- You have not had any cancer treatment before for this breast cancer (no chemo, radiation, targeted therapy, or hormone therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This Phase 3 study tests giving trastuzumab and pertuzumab as additional (adjuvant) treatment after you had those same medicines before surgery but still had remaining cancer. It may help lower the chance that HER2-positive breast cancer comes back.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.